Company

InnoCare Pharma Ltd

Headquarters: Beijing, China

Employees: 531

CEO: Dr. Jisong Cui

HKEX: 9969 -0.64%

Market Cap

HK$12.18 Billion

HKD as of Jan. 1, 2024

US$1.56 Billion

Market Cap History

InnoCare Pharma Ltd market capitalization over time

Evolution of InnoCare Pharma Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of InnoCare Pharma Ltd

Detailed Description

InnoCare Pharma Limited, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It offers Orelabrutinib (ICP-022), a Bruton's tyrosine kinase for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma, and relapsed and refractory mantle cell lymphoma. ICP-022 is in Phase II studies for patients with relapsed and refractory marginal zone lymphoma, relapsed and refractory central nervous system lymphoma, and relapsed and refractory Waldenstrom's macroglobulinemia; and in a Phase I clinical trial for follicular lymphoma patients, as well as Phase I basket trial for B-cell malignancies. The company is developing Gunagratinib( ICP-192), a pan-inhibitor of fibroblast growth factor receptor (FGFR) that is in Phase I/IIa clinical trial to define its maximum tolerated dose and/or optimal biological dose, and pharmacokinetics/ pharmacodynamics in patients with solid tumors; and ICP-105, a FGFR4 inhibitor, which is in Phase I dose escalation trial for the treatment of advanced hepatocellular carcinoma. It is also developing ICP-723, a pan-inhibitor of tropomyosin-related kinase family that is in Phase I clinical trial to treat patients with neurotrophic tyrosine receptor kinase fusion-positive cancers; and ICP-332, a small-molecule inhibitor of tyrosine kinase 2 for the treatment of various T-cell mediated autoimmune disorders, such as psoriasis, inflammatory bowel disease, and systemic lupus erythematosus. The company was incorporated in 2015 and is headquartered in Beijing, China.

Top 1-year algo backtest: +287.69%

$10,000 in March 2023 would now be $38,769 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

InnoCare Pharma Ltd has the following listings and related stock indices.


Stock: HKEX: 9969 wb_incandescent

Details

Headquarters:

Zhongguancun Life Science Park

Building 8 No. 8 Life Science Park Road Changping District

Beijing, 102206

China

Phone: 86 10 6660 9999

Fax: 86 10 6070 2992